174 related articles for article (PubMed ID: 22810479)
21. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
22. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
23. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Russo A; Bazan V; Agnese V; Rodolico V; Gebbia N
Ann Oncol; 2005 May; 16 Suppl 4():iv44-49. PubMed ID: 15923428
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer.
González-Aguilera JJ; Oliart S; Azcoita MM; Fernández-Peralta AM
Am J Clin Oncol; 2004 Feb; 27(1):39-45. PubMed ID: 14758132
[TBL] [Abstract][Full Text] [Related]
26. The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses: a meta-analysis of prospective studies.
Fuccio L; Hassan C; Laterza L; Correale L; Pagano N; Bocus P; Fabbri C; Maimone A; Cennamo V; Repici A; Costamagna G; Bazzoli F; Larghi A
Gastrointest Endosc; 2013 Oct; 78(4):596-608. PubMed ID: 23660563
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Chang HJ; Kim HK; Joo KR; Lee JI
Medicine (Baltimore); 2017 Sep; 96(35):e7882. PubMed ID: 28858102
[TBL] [Abstract][Full Text] [Related]
28. K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011.
Ruiz-Candelaria Y; Miranda-Diaz C; Hunter-Mellado RF
Int J Biol Markers; 2013 Dec; 28(4):e393-7. PubMed ID: 23999847
[TBL] [Abstract][Full Text] [Related]
29. No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.
Kimura K; Nagasaka T; Hoshizima N; Sasamoto H; Notohara K; Takeda M; Kominami K; Iishii T; Tanaka N; Matsubara N
J Int Med Res; 2007; 35(4):450-7. PubMed ID: 17697521
[TBL] [Abstract][Full Text] [Related]
30. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer.
Yan ZH; Cui LH; Wang XH; Li C; He X
World J Gastroenterol; 2014 Dec; 20(48):18338-45. PubMed ID: 25561800
[TBL] [Abstract][Full Text] [Related]
32. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
33. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
35. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.
Akkiprik M; Celikel CA; Düşünceli F; Sönmez O; Güllüoğlu BM; Sav A; Ozer A
Turk J Gastroenterol; 2008 Mar; 19(1):22-7. PubMed ID: 18386236
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
37. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
38. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Barault L; Veyrie N; Jooste V; Lecorre D; Chapusot C; Ferraz JM; Lièvre A; Cortet M; Bouvier AM; Rat P; Roignot P; Faivre J; Laurent-Puig P; Piard F
Int J Cancer; 2008 May; 122(10):2255-9. PubMed ID: 18224685
[TBL] [Abstract][Full Text] [Related]
40. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
Tortola S; Marcuello E; González I; Reyes G; Arribas R; Aiza G; Sancho FJ; Peinado MA; Capella G
J Clin Oncol; 1999 May; 17(5):1375-81. PubMed ID: 10334521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
